Pharmacotherapies for obesity: Past, current, and future therapies

Journal of Obesity

Volumn 2011, Issue , 2011, Pages

  Ioannides Demos, Lisa L ^a   Piccenna, Loretta ^a   McNeil, John J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857425784     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2011/179674     Document Type: Review

References (149)

1. Ioannides-Demos L. L., Proietto J., McNeil J. J., Pharmacotherapy for obesity. Drugs 2005 65 10 1391 1418 2-s2.0-22944466685 10.2165/00003495- 200565100-00006 (Pubitemid 41043893)
2. Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., Higenbottam T., Oakley C., Wouters E., Aubier M., Simonneau G., Bégaud B., Appetite-suppressant drugs and the risk of primary pulmonary hypertension. The New England Journal of Medicine 1996 335 9 609 616 2-s2.0-9444287592 10.1056/NEJM199608293350901 (Pubitemid 26277950)
3. Ioannides-Demos L. L., Proietto J., Tonkin A. M., McNeil J. J., Safety of drug therapies used for weight loss and treatment of obesity. Drug Safety 2006 29 4 277 302 2-s2.0-33645468559 10.2165/00002018-200629040-00001
4. Jick H., Vasilakis C., Weinrauch L. A., Meier C. R., Jick S. S., Derby L. E., A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. The New England Journal of Medicine 1998 339 11 719 724 2-s2.0-0032504983 10.1056/NEJM199809103391102 (Pubitemid 28417354)
5. Loke Y. K., Derry S., Pritchard-Copley A., Appetite suppressants and valvular heart disease-a systematic review. BMC Clinical Pharmacology 2002 2, article 6 2-s2.0-0003376125 10.1186/1472-6904-2-6 (Pubitemid 38751340)
6. Sachdev M., Miller W. C., Ryan T., Jollis J. G., Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. American Heart Journal 2002 144 6 1065 1073 2-s2.0-0036911037 10.1067/mhj.2002.126733 (Pubitemid 36026921)
7. Glazer G., Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Archives of Internal Medicine 2001 161 15 1814 1824 2-s2.0-0034890568 (Pubitemid 32762724)
8. Kernan W. N., Viscoli C. M., Brass L. M., Broderick J. P., Brott T., Feldmann E., Morgenstern L. B., Wilterdink J. L., Horwitz R. I., Phenylpropanolamine and the risk of hemorrhagic stroke. The New England Journal of Medicine 2000 343 25 1826 1832 2-s2.0-0034700436 10.1056/NEJM200012213432501 (Pubitemid 32104127)
9. Christensen R., Kristensen P. K., Bartels E. M., Bliddal H., Astrup A., Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. The Lancet 2007 370 9600 1706 1713 2-s2.0-36048995288 10.1016/S0140-6736(07)61721-8 (Pubitemid 350100788)
10. European Medicines Agency. Withdrawal of the marketing authorisation in the European Union, 2009, http://www.emea.europa.eu/humandocs/PDFs/EPAR/zimulti/ 3956009en.pdf
11. Mitchell P. B., Morris M. J., Depression and anxiety with rimonabant. The Lancet 2007 370 9600 1671 1672 2-s2.0-36049006465 10.1016/S0140-6736(07)61705-X (Pubitemid 350100780)
12. Stiles, S. FDA:Excess of CV events with sibutramine in SCOUT. HeartWire News, http://www.theheart.org/article/1027617/print.do
13. Caterson I., Ian.Caterson@usyd.edu.au Coutinho W., Finer N., Van Gaal L., Maggioni A., Torp-Pedersen C., Sharma A. M., Ge H., Santoro D., Shepherd G., James P., Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity 2010 18 5 987 994 10.1038/oby.2009.327
14. Van Gaal L., Caterson I., Coutinho W., on behalf of the SCOUT Investigators. Weight and blood pressure response to weight management and sibutramine in diabetic and non diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. Diabetes. Obesity and Metabolism 2010 12 26 34
15. Weeke P., Andersson C., Fosbøl E. L., Brendorp B., Kober L., Sharma A. M., Finer N., James P. T., Caterson I. D., Rode R. A., Torp-Pedersen C., The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus-an analysis from the SCOUT lead-in period. BMC Endocrine Disorders 2010 10, article 3 10.1186/1472-6823-10-3
16. Williams G., Withdrawal of sibutramine in Europe. British Medical Journal 2010 340, article c824 10.1136/bmj.c824
17. James W. P.T., jeanhjames@aol.com Caterson I. D., Coutinho W., Finer N., Van Gaal L. F., Maggioni A. P., Torp-Pedersen C., Sharma A. M., Shepherd G. M., Rode R. A., Renz C. L., Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. The New England Journal of Medicine 2010 363 10 905 917 10.1056/NEJMoa1003114
18. Barbosa M. D. F. S., Celis E., Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses. Drug Discovery Today 2007 12 15-16 674 681 2-s2.0-34547743906 10.1016/j.drudis.2007.06.005 (Pubitemid 47238643)
19. Fabricatore A. N., Wadden T. A., Moore R. H., Butryn M. L., Gravallese E. A., Erondu N. E., Heymsfield S. B., Nguyen A. M., Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis: obesity Management. Obesity Reviews 2009 10 3 333 341 2-s2.0-65349107671 10.1111/j.1467-789X.2009.00567.x
20. Johansson K., Neovius K., Desantis S. M., Rössner S., Neovius M., Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obesity Reviews 2009 10 5 564 575 2-s2.0-69449091278 10.1111/j.1467-789X.2009.00581.x
21. McGovern L., Johnson J. N., Paulo R., Hettinger A., Singhal V., Kamath C., Erwin P. J., Montori V. M., Treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials. Journal of Clinical Endocrinology and Metabolism 2008 93 12 4600 4605 2-s2.0-57349174466 10.1210/jc.2006-2409
22. Greenway F. L., frank.greenway@pbrc.edu Dunayevich E., Tollefson G., Erickson J., Guttadauria M., Fujioka K., Cowley M. A., Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. Journal of Clinical Endocrinology and Metabolism 2009 94 12 4898 4906 10.1210/jc.2009-1350
23. Aronne L. J., ljaronne@med.cornell.edu Tonstad S., Moreno M., Gantz I., Erondu N., Suryawanshi S., Molony C., Sieberts S., Nayee J., Meehan A. G., Shapiro D., Heymsfield S. B., Kaufman K. D., Amatruda J. M., A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. International Journal of Obesity 2010 34 5 919 935 10.1038/ijo.2010.21
24. Bermudez-Silva F. J., franciscoj.bermudez@fundacionimabis.org Viveros M. P., McPartland J. M., Rodriguez de Fonseca F., The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacology Biochemistry and Behavior 2010 95 4 375 382 10.1016/j.pbb.2010.03.012
25. Li M., Cheung B. M. Y., Pharmacotherapy for obesity. British Journal of Clinical Pharmacology 2009 68 6 804 810 2-s2.0-70849093104 10.1111/j.1365-2125. 2009.03453.x
26. Padwal R. S., Majumdar S. R., Drug treatments for obesity: orlistat, sibutramine, and rimonabant. The Lancet 2007 369 9555 71 77 2-s2.0-33845874637 10.1016/S0140-6736(07)60033-6 (Pubitemid 46027230)
27. Munro J. F., MacCuish A. C., Wilson E. M., Duncan L. J., Comparison of continuous and intermittent anorectic therapy in obesity. British medical journal 1968 1 5588 352 354 2-s2.0-0001661402
28. Weintraub M., Hasday J. D., Mushlin A. I., Lockwood D. H., A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Archives of Internal Medicine 1984 144 6 1143 1148 2-s2.0-0021242404 10.1001/archinte.144.6.1143 (Pubitemid 14121061)
29. Griffen L., Anchors M., The "phen-pro" diet drug combination is net associated with valvular heart disease. Archives of Internal Medicine 1998 158 11 1278 1279 2-s2.0-0032496607 10.1001/archinte.158.11.1278 (Pubitemid 28252498)
30. Haddock C. K., Poston W. S. C., Dill P. L., Foreyt J. P., Ericsson M., Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. International Journal of Obesity 2002 26 2 262 273 2-s2.0-0036178685 10.1038/sj/ijo/0801889 (Pubitemid 34151206)
31. McKay R. H., Long-term use of diethylpropion in obesity. Current Medical Research and Opinion 1973 1 8 489 493 2-s2.0-0015871393
32. Cercato C., Roizenblatt V. A., Leança C. C., Segal A., Lopes Filho A. P., Mancini M. C., Halpern A., A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. International Journal of Obesity 2009 33 8 857 865 2-s2.0-68949158460 10.1038/ijo.2009.124
33. Garfield A. S., Heisler L. K., Pharmacological targeting of the serotonergic system for the treatment of obesity. Journal of Physiology 2009 587 1 49 60 2-s2.0-58149301316 10.1113/jphysiol.2008.164152
34. Heisler L. K., Cowley M. A., Tecott L. H., Fan W., Low M. J., Smart J. L., Rubinstein M., Tatro J. B., Marcus J. N., Holstege H., Lee C. E., Cone R. D., Elmquist J. K., Activation of central melanocortin pathways by fenfluramine. Science 2002 297 5581 609 611 2-s2.0-0037178730 10.1126/science.1072327 (Pubitemid 34815346)
35. Heisler L. K., Pronchuk N., Nonogaki K., Zhou L., Raber J., Tung L., Yeo G. S. H., O'Rahilly S., Colmers W. F., Elmquist J. K., Tecott L. H., Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2C receptor stimulation. Journal of Neuroscience 2007 27 26 6956 6964 2-s2.0-34347360837 10.1523/JNEUROSCI.2584-06.2007 (Pubitemid 47015900)
36. Lam D. D., Przydzial M. J., Ridley S. H., Yeo G. S. H., Rochford J. J., O'Rahilly S., Heisler L. K., Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 2008 149 3 1323 1328 2-s2.0-40849135860 10.1210/en.2007-1321 (Pubitemid 351397929)
37. Carvajal A., Garcia del Pozo J., Martin de Diego I., Rueda de Castro A. M., Velasco A., Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: a meta-analysis. Methods and Findings in Experimental and Clinical Pharmacology 2000 22 5 285 290 2-s2.0-0033847148 (Pubitemid 30664414)
38. Guy-Grand B., Appelbaum M., Crepaldi G., Gries A., Lefebvre P., Turner P., International trial of long-term dexfenfluramine in obesity. The Lancet 1989 2 8672 1142 1145 2-s2.0-0024446507 (Pubitemid 19267116)
39. Mathus-Vliegen E. M. H., van de Voorde K., Kok A. M. E., Res A. M. A., Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour. Journal of Internal Medicine 1992 232 2 119 127 2-s2.0-0026655476
40. Weintraub M., Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study: introduction. Clinical Pharmacology and Therapeutics 1992 51 5 581 585 2-s2.0-0026517115
41. Bowen R., Glicklich A., Khan M., Rasmussen S., Wadden T., Bustad J., Graham D., Green L., Lumpkin M., O'Neill R., Sobel S., Hubbard V. S., Yanovski S., Sopko G., Cardiac valvulopathy associated with exposure fenfluramine or dexfenfluramine: US Department of Health and Human Services Interim Public Health Recommendations, November 1997. MMWR 1997 46 45 1061 1066
42. Curfman G. D., Diet pills redux. The New England Journal of Medicine 1997 337 9 629 630 2-s2.0-0030838580 10.1056/NEJM199708283370909 (Pubitemid 27360765)
43. Delcroix M., Kurz X., Walckiers D., Demedts M., Naeije R., High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium. European Respiratory Journal 1998 12 2 271 276 2-s2.0-0031844306 (Pubitemid 28389517)
44. Levine L. R., Enas G. G., Thompson W. L., Byyny R. L., Dauer A. D., Kirby R. W., Kreindler T. G., Levy B., Lucas C. P., McIlwain H. H., Nelson E. B., Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. International Journal of Obesity 1989 13 5 635 645 (Pubitemid 20004812)
45. Bray G. A., Use and abuse of appetite-suppressant drugs in the treatment of obesity. Annals of Internal Medicine 1993 119 7 707 713 2-s2.0-0027363269 (Pubitemid 23313694)
46. Goldstein D. J., Rampey A. H., Enas G. G., Fluoxetine: a randomised clinical trial in the treatment of obesity. International Journal of Obesity 1994 18 129 135 (Pubitemid 24087126)
47. Wise S. D., Clinical studies with fluoxetine in obesity. American Journal of Clinical Nutrition 1992 55 1 181S 184S 2-s2.0-0026504664
48. Darga L. L., Carroll-Michals L., Botsford S. J., Lucas C. P., Fluoxetine's effect on weight loss in obese subjects. American Journal of Clinical Nutrition 1991 54 2 321 325 2-s2.0-0025879632 (Pubitemid 21898937)
49. Pedrinola F., Sztejnsznajd C., Lima N., Halpern A., Medeiros-Neto G., The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial. Obesity Research 1996 4 6 549 554 2-s2.0-0030278088 (Pubitemid 126690159)
50. Anchors M., Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity. Archives of Internal Medicine 1997 157 11 1270 2-s2.0-0030967598 (Pubitemid 27251661)
51. Whigham L. D., Dhurandhar N. V., Rahko P. S., Atkinson R. L., Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status. International Journal of Obesity 2007 31 5 850 857 2-s2.0-34247544381 10.1038/sj.ijo.0803498 (Pubitemid 46663820)
52. Plodkowski R. A., Nguyen Q., Sundaram U., Nguyen L., Chau D. L., St Jeor S., Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opinion on Pharmacotherapy 2009 10 6 1069 1081 2-s2.0-67649641596 10.1517/14656560902775750
53. Anderson J. W., Greenway F. L., Fujioka K., Gadde K. M., McKenney J., O'Neil P. M., Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obesity Research 2002 10 7 633 641 2-s2.0-0036636368 (Pubitemid 135688262)
54. Croft H., Houser T., Leadbetter R., Jamerson B., Effect of bupropion SR on weight in the long-term treatment of depression. Obesity Research 2000 8 supplement 1 10
55. Gadde K. M., Parker C. B., Maner L. G., Wagner H. R. II, Logue E. J., Drezner M. K., Krishnan K. R. R., Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obesity Research 2001 9 9 544 551 2-s2.0-0035463417 (Pubitemid 33610175)
56. Li Z., Maglione M., Tu W., Mojica W., Arterburn D., Shugarman L. R., Hilton L., Suttorp M., Solomon V., Shekelle P. G., Morton S. C., Meta-analysis: pharmacologic treatment of obesity. Annals of Internal Medicine 2005 142 7 532 546 2-s2.0-15944367788
57. Padwal R., Li S. K., Lau D. C., Long-term pharmacotherapy for obesity and overweight. Cochrane Database of Systematic Reviews 2004 4 3 CD004094
58. Rucker D., Padwal R., Li S. K., Curioni C., Lau D. C. W., Long term pharmacotherapy for obesity and overweight: updated meta-analysis. British Medical Journal 2007 335 7631 1194 1199 2-s2.0-37249083878 10.1136/bmj.39385. 413113.25 (Pubitemid 350273303)
59. Neovius M., Johansson K., Rössner S., Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis. Obesity Reviews 2008 9 5 420 427 2-s2.0-49649101096 10.1111/j.1467-789X.2008.00463.x
60. Curioni C., André C., Rimonabant for overweight or obesity. Cochrane Database of Systematic Reviews 2006 4 CD006162 2-s2.0-39049181862
61. Hauptman J., Lucas C., Boldrin M. N., Collins H., Segal K. R., Orlistat in the long-term treatment of obesity in primary care settings. Archives of Family Medicine 2000 9 2 160 167 2-s2.0-0033829586
62. Heymsfield S. B., Segal K. R., Hauptman J., Lucas C. P., Boldrin M. N., Rissanen A., Wilding J. P. H., Sjöström L., Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Archives of Internal Medicine 2000 160 9 1321 1326 2-s2.0-0034621494 (Pubitemid 30252779)
63. Rössner S., stephan.rossner@medhs.ki.se Sjöström L., Noack R., Meinders A. E., Noseda G., Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obesity Research 2000 8 1 49 61
64. Torgerson J. S., Hauptman J., Boldrin M. N., Sjöström L., XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 27 1 155 161 2-s2.0-1042303480 10.2337/diacare.27.1.155 (Pubitemid 38196725)
65. Horvath K., Jeitler K., Siering U., Stich A. K., Skipka G., Gratzer T. W., Siebenhofer A., Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Archives of Internal Medicine 2008 168 6 571 580 2-s2.0-41549096849 10.1001/archinte.168.6.571 (Pubitemid 351468391)
66. Siebenhofer A., Horvath K., Jeitler K., Berghold A., Stich A. K., Matyas E., Pignitter N., Siering U., Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database of Systematic Reviews 2009 3 CD007654 2-s2.0-68549107708
67. Franz M. J., VanWormer J. J., Crain A. L., Boucher J. L., Histon T., Caplan W., Bowman J. D., Pronk N. P., Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. Journal of the American Dietetic Association 2007 107 10 1755 1767 2-s2.0-34648836960 10.1016/j.jada.2007.07.017 (Pubitemid 47464109)
68. Hutton B., Fergusson D., Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. American Journal of Clinical Nutrition 2004 80 6 1461 1468 2-s2.0-16544369107 (Pubitemid 41103841)
69. O'Meara S., Riemsma R., Shirran L., Mather L., Ter Riet G., A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obesity Reviews 2004 5 1 51 68 2-s2.0-0842312437 10.1111/j.1467-789X. 2004.00125.x (Pubitemid 38173594)
70. Padwal R., rpadwal@yahoo.com Li S. K., Lau D. C.W., Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. International Journal of Obesity 2003 27 12 1437 1446 10.1038/sj.ijo.0802475 (Pubitemid 38019154)
71. Czernichow S., czernichow@uren.smbh.univ-paris13.fr Lee C. M.Y., Barzi F., Greenfield J. R., Baur L. A., Chalmers J., Woodward M., Huxley R. R., Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials. Obesity Reviews 2010 11 2 150 158 10.1111/j.1467-789X.2009.00620.x
72. FDA Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury, 2010, http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm179166.htm
73. Connoley I. P., Liu Y.-L., Frost I., Reckless I. P., Heal D. J., Stock M. J., Thermogenic effects of sibutramine and its metabolites. British Journal of Pharmacology 1999 126 6 1487 1495 2-s2.0-0033036174 (Pubitemid 29142081)
74. Jones S. P., Smith I. G., Kelly F., Gray J. A., Long term weight loss with sibutramine. International Journal of Obesity 1995 19 supplement 2 41
75. Apfelbaum M., Vague P., Ziegler O., Hanotin C., Thomas F., Leutenegger E., Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. American Journal of Medicine 1999 106 2 179 184 2-s2.0-0033082197 10.1016/S0002-9343(98)00411-2 (Pubitemid 29115958)
76. Bray G. A., Ryan D. H., Gordon D., Heidingsfelder S., Cerise F., Wilson K., A double-blind randomized placebo-controlled trial of sibutramine. Obesity Research 1996 4 3 263 270 2-s2.0-0030147221 (Pubitemid 126690229)
77. Smith I. G., Goulder M. A., Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. Journal of Family Practice 2001 50 6 505 512 2-s2.0-0034965112 (Pubitemid 32538668)
78. James W. P. T., Astrup A., Finer N., Hilsted J., Kopelman P., Rössner S., Saris W. H. M., Van Gaal L. F., Effect of sibutramine on weight maintenance after weight loss: a randomised trial. The Lancet 2000 356 2119 2125 2-s2.0-0034516930 10.1016/S0140-6736(00)03491-7 (Pubitemid 32047947)
79. McMahon F. G., Fujioka K., Singh B. N., Mendel C. M., Rowe E., Rolston K., Johnson F., Mooradian A. D., Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Archives of Internal Medicine 2000 160 14 2185 2191 2-s2.0-0034710218 (Pubitemid 30482726)
80. Smith I. G., Jones S. P., Heath M. J., Kelly F., Categorical outcome analysis of weight loss in long-term sibutramine. International Journal of Obesity 1996 20 157
81. Johansson K., Sundström J., Neovius K., Rössner S, Neovius M., Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Obesity Reviews 2009 11 11 777 791 10.1111/j.1467-789X.2009.00693.x
82. Wadden T. A., Berkowitz R. I., Sarwer D. B., Prus-Wisniewski R., Steinberg C., Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Archives of Internal Medicine 2001 161 2 218 227 2-s2.0-0035931331 (Pubitemid 32102389)
83. Wadden T. A., Berkowitz R. I., Womble L. G., Sarwer D. B., Arnold M. E., Steinberg C. M., Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obesity Research 2000 8 6 431 437 2-s2.0-0034264256
84. Sari R., Balci M. K., Cakir M., Altunbas H., Karayalcin U., Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocrine Research 2004 30 2 159 167 2-s2.0-4544276140 10.1081/ERC-200027356 (Pubitemid 39243118)
85. Aronne L. J., Halseth A. E., Burns C. M., Miller S., Shen L. Z., lshen@amylin.com Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity 2010 18 9 1739 1746 10.1038/oby.2009.478
86. James W. P. T., The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. European Heart Journal, Supplement 2005 7 L44 L48 2-s2.0-27744466523 10.1093/eurheartj/sui086 (Pubitemid 41630392)
87. Sharma A. M., sharma@obesitynetwork.ca Caterson I. D., Coutinho W., Finer N., Van Gaal L., Maggioni A. P., Torp-Pedersen C., Bacher H. P., Shepherd G. M., James W. P.T., Blood pressure changes associated with sibutramine and weight management-an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes, Obesity and Metabolism 2009 11 3 239 250 10.1111/j.1463-1326.2008.00930.x
88. Von Haehling S., Lainscak M., Anker S. D., Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon? European Heart Journal 2007 28 23 2830 2831 2-s2.0-36849017966 10.1093/eurheartj/ehm493 (Pubitemid 350233044)
89. Torp-Pedersen C., Caterson I., Coutinho W., Finer N., Van Gaal L., Maggioni A., Sharma A., Brisco W., Deaton R., Shepherd G., James P., Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. European Heart Journal 2007 28 23 2915 2923 2-s2.0-36849095595 10.1093/eurheartj/ehm217 (Pubitemid 350233016)
90. GLG Expert Contributor. New Meridia SCOUT trial has major implications for obesity drug development, 2009, http://www.glgroup.com/News/New-Meridia- SCOUT-Trial-has-Major-Implications-for-Obesity-Drug-Development-45006.html
91. FDA Drug Safety Communication: Follow-Up to the November 2009 Early Communication about an Ongoing Safety Review of Sibutramine, Marketed as Meridia, 2010, http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm198206.htm
92. Singer N., Pollack A.,. Heart Patients Warned Against Using Meridia, an Anti-Obesity Drug. The New York Times, 2010, http://www.nytimes.com/2010/01/23/ business/23diet.html
93. Harrison-Woolrych M., mira.harrison-woolrych@otago.ac.nz Ashton J., Herbison P., Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study. Drug Safety 2010 33 7 605 613 10.2165/11532440-000000000-00000
94. Astrup A., Drug management of obesity-efficacy versus safety. The New England Journal of Medicine 2010 363 3 288 290 10.1056/NEJMe1004076
95. Cahill K., Ussher M., Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database of Systematic Reviews 2007 4 CD005353 2-s2.0-35348879969
96. Van Gaal L., Pi-Sunyer X., Després J. P., McCarthy C., Scheen A., Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes care 2008 31 supplement 2 S229 240 2-s2.0-41149130137
97. Fujioka K., Apovian C., Hill J.,. The Evolution of Obesity Therapies: New Applications for Existing Drugs. MedscapeCME Diabetes Endocrinology, 2010, http://cme.medscape.com/viewarticle/722366
98. Nissen S. E., Nicholls S. J., Wolski K., Rodés-Cabau J., Cannon C. P., Deanfield J. E., Després J.-P., Kastelein J. J. P., Steinhubl S. R., Kapadia S., Yasin M., Ruzyllo W., Gaudin C., Job B., Hu B., Bhatt D. L., Lincoff A. M., Tuzcu E. M., Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008 299 13 1547 1560 2-s2.0-41649090426 10.1001/jama.299.13.1547 (Pubitemid 351482794)
99. Astrup A., Madsbad S., Breum L., Jensen T., Kroustrup J., Larsen T., Effect of tesofensine on bodyweight loss body composion and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. The Lancet 2008 372 1906 1913
100. Chavez-Tapia N. C., Tellez-Avila F. I., Bedogni G., Crocè L. S., Masutti F., Tiribelli C., Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology. BMC Gastroenterology 2009 9, article no. 1471 75 2-s2.0-70449514093 10.1186/1471-230X-9-75
101. Berton E., Bender R.,. UPDATE: Sanofi-Aventis stops all Acomplia clinical trials. Dow Jones Newswires, 2008, www.djnewswires.com
102. McTigue K. M., Hess R., Ziouras J., Obesity in older adults: a systematic review of the evidence for diagnosis and treatment. Obesity 2006 14 9 1485 1497 2-s2.0-33846846438 10.1038/oby.2006.171 (Pubitemid 46214814)
103. Oude Luttikhuis H., Baur L., Jansen H., Shrewsbury V. A., O'Malley C., Stolk R. P., Summerbell C. D., Interventions for treating obesity in children. Cochrane Database of Systematic Reviews 2009 1 CD001872 2-s2.0-62449279686
104. Viner R. M., r.viner@ich.ucl.ac.uk Hsia Y., Tomsic T., Wong I. C.K., Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis: obesity management. Obesity Reviews 2010 11 8 593 602 10.1111/j.1467-789X.2009.00651.x
105. Gadde K. M., Allison D. B., Combination pharmaceutical therapies for obesity. Expert Opinion on Pharmacotherapy 2009 10 6 921 925 2-s2.0-67649631173 10.1517/14656560902824152
106. Valentino M. A., Lin J. E., Waldman S. A., Scott.Waldman@jefferson.edu Central and peripheral molecular targets for antiobesity pharmacotherapy. Clinical Pharmacology and Therapeutics 2010 87 6 652 662 10.1038/clpt.2010.57
107. Aronne L., Fujioka K., Aroda V., Chen K., Halseth A., Kesty N. C., Burns C., Lush C. W., Weyer C., cweyer@amylin.com Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. Journal of Clinical Endocrinology and Metabolism 2007 92 8 2977 2983 10.1210/jc.2006-2003 (Pubitemid 47236359)
108. Smith S. R., Aronne L. J., Burns C. M., Kesty N. C., Halseth A. E., Weyer C., Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008 31 9 1816 1823 2-s2.0-56149124659 10.2337/dc08-0029
109. Vilsbøll T., Zdravkovic M., Le-Thi T., Krarup T., Schmitz O., Courrèges J.-P., Verhoeven R., Bugánová I., Madsbad S., Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007 30 6 1608 1610 2-s2.0-34249869806 10.2337/dc06-2593 (Pubitemid 46871185)
110. Madsbad S., Liraglutide effect and action in diabetes (LEAD) trial. Expert Review of Endocrinology and Metabolism 2009 4 2 119 129 2-s2.0-67649189310 10.1586/17446651.4.2.119
111. Nauck M., Frid A., Hermansen K., Shah N. S., Tankova T., Mitha I. H., Zdravkovic M., Düring M., Matthews D. R., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care 2009 32 1 84 90 10.2337/dc08-1355
112. Astrup A., ast@life.ku.dk Rössner S., Van Gaal L., Rissanen A., Niskanen L., Al Hakim M., Madsen J., Rasmussen M. F., Lean M. E., Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. The Lancet 2009 374 9701 1606 1616 10.1016/S0140-6736(09)61375-1
113. Meade L. T., lmeade@catawbavalleymc.org Practical use of exenatide and pramlintide for the treatment of type 2 diabetes. Journal of Pharmacy Practice 2009 22 6 540 545 10.1177/0897190009333164
114. Blonde L., Klein E. J., Han J., Zhang B., Mac S. M., Poon T. H., Taylor K. L., Trautmann M. E., Kim D. D., Kendall D. M., Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2006 8 4 436 447 2-s2.0-33748442464 10.1111/j.1463-1326.2006. 00602.x (Pubitemid 44349236)
115. Addy C., Wright H., Van Laere K., Gantz I., Erondu N., Musser B. J., Lu K., Yuan J., Sanabria-Bohórquez S. M., Stoch A., Stevens C., Fong T. M., De Lepeleire I., Cilissen C., Cote J., Rosko K., Gendrano I. N. III, Nguyen A. M., Gumbiner B., Rothenberg P., de Hoon J., Bormans G., Depré M., Eng W.-S., Ravussin E., Klein S., Blundell J., Herman G. A., Burns H. D., Hargreaves R. J., Wagner J., Gottesdiener K., Amatruda J. M., Heymsfield S. B., The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metabolism 2008 7 1 68 78 2-s2.0-37449007904 10.1016/j.cmet.2007.11.012
116. Wadden T. A., Fujioka K., Toubro S., A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet. Obesity 2010 18 12 2301 2310
117. Kipnes M. S., mkipnes@dgdclinic.com Hollander P., Fujioka K., Gantz I., Seck T., Erondu N., Shentu Y., Lu K., Suryawanshi S., Chou M., Johnson-Levonas A. O., Heymsfield S. B., Shapiro D., Kaufman K. D., Amatruda J. M., A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2010 12 6 517 531 10.1111/j.1463-1326.2009.01188.x
118. Proietto J., j.proietto@unimelb.edu.au Rissanen A., Harp J. B., Erondu N., Yu Q., Suryawanshi S., Jones M. E., Johnson-Levonas A. O., Heymsfield S. B., Kaufman K. D., Amatruda J. M., A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. International Journal of Obesity 2010 34 8 1243 1254 10.1038/ijo.2010.38
119. Koch L., Obesity: taranabant no longer developed as an antiobesity agent. Nature Reviews Endocrinology 2010 6 6 300 10.1038/nrendo.2010.56
120. Smith S. R., Weissman N. J., Anderson C. M., Multicentre placebo-controlled trial of lorcaserin for weight management. The New England Journal of Medicine 2010 363 245 256
121. Wadden T. A., Foreyt J. P., Foster G. D., Weight loss with naltrexone sr/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD Trial. Obesity, 2010. In press 10.1038/oby.2010.147
122. Rosenstock J., juliorosenstock@dallasdiabetes.com Hollander P., Gadde K. M., Sun X., Strauss R., Leung A., A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care 2007 30 6 1480 1486 10.2337/dc06-2001 (Pubitemid 46871158)
123. Vivus Inc. VIVUS Announces Positive Results From Two Phase 3 Studies: Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities: Results of EQUIP and CONQUER Phase 3 Studies Exceed FDA Benchmarks for Obesity Treatments, Demonstrate Positive Safety Profile, http://ir.vivus.com/releasedetail.cfm?ReleaseID=407933
124. Connolly H. M., Crary J. L., McGoon M. D., Hensrud D. D., Edwards B. S.,
125. Chakrabarti R., Pharmacotherapy of obesity: emerging drugs and targets. Expert Opinion on Therapeutic Targets 2009 13 2 195 207 2-s2.0-64349117818 10.1517/14728220802637063
126. Idelevich E., Kirch W., Schindler C., Current pharmacotherapeutic concepts for the treatment of obesity in adults. Therapeutic Advances in Cardiovascular Disease 2009 3 1 75 90 2-s2.0-68749091398 10.1177/ 1753944708098226
127. Anderson C. M., Sanchez M., Krolikowski J., Mancini M., Shanahan W. R.,. a selective 5-HT2C agonist is efficacious for weight loss across patient subgroups. American Diabetes Association 70th Scientific Meeting. Abstract 1845-P, 2010, http://professional.diabetes.org/Abstracts-Display.aspx?TYP= 1&CID=80762
128. Fidler M. C., Sanchez M., Raether B. L., Anderson C. M., Shanahan W. R.,. Changes in glucose tolerance and cardiovascular risk factors after 52 weeks of treatment with lorcaserin. American Diabetes Association 70th Scientific Meeting. Abstract 1855-P, 2010, http://professional.diabetes.org/Abstracts- Display.aspx?TYP=1&CID=80772
129. Astrup A., Meier D. H., Mikkelsen B. O., Villumsen J. S., Larsen T. M., Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity 2008 16 6 1363 1369 2-s2.0-44449102253 10.1038/oby.2008.56 (Pubitemid 351770532)
130. Holtzman S. G., Suppression of appetitive behavior in the rat by naloxone: lack of effect of prior morphine dependence. Life Sciences 1979 24 3 219 226 2-s2.0-0018754527 (Pubitemid 9119932)
131. Atkinson R. L., Berke L. K., Drake C. R., Effects of long-term therapy with naltrexone on body weight in obesity. Clinical Pharmacology and Therapeutics 1985 38 4 419 422 2-s2.0-0022195837 (Pubitemid 16250316)
132. Bertino M., Beauchamp G. K., Engelman K., Naltrexone, an opioid blocker, alters taste perception and nutrient intake in humans. American Journal of Physiology 1991 261 1 R59 R63 2-s2.0-0025862309
133. Malcolm R., O'Neil P. M., Sexauer J. D., A controlled trial of naltrexone in obese humans. International Journal of Obesity 1985 9 5 347 353 (Pubitemid 16201361)
134. Spiegel T. A., Stunkard A. J., Shrager E. E., Effect of Naltrexone on food intake, hunger, and satiety in obese men. Physiology and Behavior 1987 40 2 135 141 (Pubitemid 17096811)
135. Cone R. D., Anatomy and regulation of the central melanocortin system. Nature Neuroscience 2005 8 5 571 578 2-s2.0-17844401704 10.1038/nn1455 (Pubitemid 40594196)
136. Grossman H. C., Hadjimarkou M. M., Silva R. M., Interrelationships between mu opiod and melanocortin receptors in mediating food intake in rats. Brain Research 2003 991 240 244 (Pubitemid 37297953)
137. Kusher R., Anti-obesity drugs. Expert Opinion on Pharmacotherapy 2008 9 1339 1350
138. Mcelroy S. L., Guerdjikova A. I., Rosen A., Kim D. D., Landbloom R., Dunayevich E.,. An open-label study evaluating the naltrexone SR/bupropion SR combination therapy in overweight or obese subjects with major depression. American Diabetes Association 70th Scientific Meeting, Abstract 1851-P, 2010, http://professional.diabetes.org/Abstracts-Display.aspx?TYP=1&CID=80768
139. Gupta A. K., Hollander P., Bays H.,. mproved glycemic control and weight loss with naltrexone SR/bupropion SR combination therapy in overweight/obese subjects with Type 2 Diabetes. American Diabetes Association 70th Scientific Meeting, Abstract 2633-PO, http://professional.diabetes.org/Abstracts-Display. aspx?TYP=1&CID=81463
140. Hollander P., Plodkowski R., Gupta A. K.,. COR-Diabetes: naltrexone SR/Bupropion SR combination therapy led to significant and sustained weight loss and improved HbA1c in overweight/obese subjects with Type 2 Diabetes. American Diabetes Association 70th Scientific Meeting, Abstract 56-OR, http://professional.diabetes.org/Abstracts-Display.aspx?TYP=1&CID=79004
141. Smith S. R., Church T., Geohas J.,. Naltrexone SR/Bupropion SR Combination Therapy Reduces Total and Visceral Adiposity in Overweight and Obese Subjects in the COR-I Study. American Diabetes Association 70th Scientific Meeting (2010). 70th Scientific Sessions, Abstract 1848-P, http://professional. diabetes.org/Abstracts-Display.aspx?TYP=1&CID=80765
142. Gadde K. M., Yonish G. M., Foust M. S., Wagner H. R. II, Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. Journal of Clinical Psychiatry 2007 68 8 1226 1229 2-s2.0-34548549373 (Pubitemid 47395625)
143. Greenway F., Anderson J., Atkinson R., Bupropion and zonisamide for the treatment of obesity [abstract 52-OR]. Obesity Research 2006 14, A17
144. Orexigen therapeutics, http://www.orexigen.com/candidates
145. Gadde K. M., Franciscy D. M., Wagner H. R. II, Krishnan K. R. R., Zonisamide for weight loss in obese adults: a randomized Controlled trial. JAMA 2003 289 14 1820 1825 2-s2.0-0038516857 10.1001/jama.289.14.1820 (Pubitemid 37430252)
146. Fujioka K., Lee M. W., Pharmacologic treatment options for obesity: current and potential medications. Nutrition in Clinical Practice 2007 22 1 50 54 2-s2.0-33846631267 10.1177/011542650702200150 (Pubitemid 46175472)
147. Kaplan L. M., Pharmacological therapies for obesity. Gastroenterology Clinics of North America 2005 34 1 91 104 2-s2.0-16844379087 10.1016/j.gtc.2004.12.002 (Pubitemid 40488734)
148. Pollack A. F. D. A.,. Panel Votes Against Obesity Drug. The New York Times, 2010, www.nytimes.com/2010/07/16/health/16obese.html?-r=1&ref=food- and-drug-administration
149. Ravussin E., Smith S. R., Mitchell J. A., Shringarpure R., Shan K., Maier H., Koda J. E., Weyer C., Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 2009 17 9 1736 1743 2-s2.0-69749086148 10.1038/oby.2009.184